GEOVAX LABS INC (GOVX)
US3736786068 - Common Stock
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will review 2024 progress in a presentation at the Biotech Showcase coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025.
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer...
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth...
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and...
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Participate in Upcoming Investor Conferences in September
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
GeoVax to Participate in Upcoming Investor Conferences in September
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and...
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
BioMedNewsBreaks — GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor
GeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share […]
Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA,...
Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Labs CEO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and...
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ...
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.